" class="no-js "lang="en-US"> Elizabeth Crawford - Medtech Alert
Thursday, April 18, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Elizabeth Crawford

Elizabeth Crawford

About Elizabeth Crawford

I am the CEO of University of Manchester spin-out, Clin-e-cal, developing innovative digital solutions in respiratory medicine. I am passionate about innovation and getting real-life, useful, solutions to people who need them.

Related Story

Diseases

 Research Presented at RDD 2021 Suggests That Acoustic Technology Is a Viable Alternative to High-cost Electronic Smart Inhalers | Pharmtech Focus

Research Presented at RDD 2021 Suggests That Acoustic Technology Is a Viable Alternative to High-cost Electronic Smart Inhalers

May 10 2021

Research presented at the Respiratory Drug Delivery (RDD) 2021 conference suggests that inhalers using acoustic […]